JAPhA Practice Innovations最新文献

{"title":"Assessing the effectiveness of patient-pharmacist communication during medication counseling in Texas community pharmacies","authors":"Kendall McKenzie,&nbsp;Amanda R. Stallings,&nbsp;Elizabeth Unni","doi":"10.1016/j.japhpi.2026.100106","DOIUrl":"10.1016/j.japhpi.2026.100106","url":null,"abstract":"<div><h3>Background</h3><div>Pharmacists, especially those in community settings, are well-positioned to reinforce medication understanding at the point of counseling, yet it remains unclear whether patients truly retain this information. There is a lack of understanding regarding the concordance between what pharmacists communicate and what patients perceive or recall.</div></div><div><h3>Objective</h3><div>To evaluate communication concordance between pharmacists and patients during counseling in community pharmacy settings.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted with 87 pharmacist–patient dyads across three Texas grocery store pharmacies. Both parties completed a five-item survey, including four closed-ended and one open-ended item. Concordance rates and demographic correlations were analyzed.</div></div><div><h3>Results</h3><div>Closed-ended item concordance was high (97.7%–100%), indicating strong agreement on structured counseling topics. Open-ended responses showed only 37.93% concordance, suggesting variability in perceived key takeaways. Patient age had a mild positive correlation with concordance (r = 0.324), while gender, ethnicity, insurance, and health literacy had no meaningful associations.</div></div><div><h3>Conclusion</h3><div>While pharmacists reliably deliver key medication information, discrepancies in open-ended recall point to a need for enhancing patient engagement and confirming understanding.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing and evaluating point-of-care testing services in a rural independent community pharmacy","authors":"Brice Wagner,&nbsp;Justin Kirby","doi":"10.1016/j.japhpi.2026.100103","DOIUrl":"10.1016/j.japhpi.2026.100103","url":null,"abstract":"<div><h3>Background</h3><div>Pharmacists have increasingly expanded their scope of practice beyond medication dispensing, embracing roles such as immunizations and medication-therapy management. Point-of-care testing (POCT) represents the latest evolution, offering rapid diagnostics and timely interventions. State-specific pharmacist scope of practice laws across the country allow for various pharmacist-directed service lines. Many expansion opportunities exist, especially in rural areas.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate patient acceptance, satisfaction, and perceptions of pharmacist-led POCT services provided at an independent rural pharmacy.</div></div><div><h3>Methods</h3><div>A prospective service evaluation was performed at an independent pharmacy in western Tennessee. Between November 2024 and March 2025, 36 patients visited the pharmacy-practice site with influenza, coronavirus disease 2019, or streptococcal pharyngitis symptoms and participated in pharmacist-led POCT. After the POCT encounter, patients completed an exit survey assessing satisfaction, perceived professionalism, likelihood of repeat use, and overall acceptance of pharmacist-provided testing. Survey data were analyzed using descriptive statistics.</div></div><div><h3>Results</h3><div>Of the 36 respondents, 35 (97%) rated their service experience highly (9 or 10 on a 10-point scale). Thirty-three patients (92%) indicated willingness to return for future testing under similar circumstances. All participants equated the professionalism of pharmacist-led POCT to that expected from traditional physician offices or urgent-care clinics. Convenience and rapid service were commonly cited advantages.</div></div><div><h3>Conclusion</h3><div>This study demonstrates high patient acceptance and satisfaction with pharmacist-led POCT in a rural pharmacy setting. The findings suggest that pharmacists are effectively positioned to address health care access issues in rural communities, providing a vital alternative to traditional health care facilities. Further support through policy development, training, and reimbursement optimization is essential to integrate and expand these services sustainably.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100103"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of GLP-1 and GIP/GLP-1 agonist access barriers in primary care","authors":"Alexandra Cochran,&nbsp;Laura Schalliol,&nbsp;Holly Lowe,&nbsp;Savannah Owen,&nbsp;Gabriella V. Rosellini","doi":"10.1016/j.japhpi.2025.100081","DOIUrl":"10.1016/j.japhpi.2025.100081","url":null,"abstract":"<div><h3>Background</h3><div>Access to glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists is frequently limited by medication shortages, insurance restrictions, and financial barriers. These medications are critical tools for glycemic control and weight management in patients with type 2 diabetes mellitus (T2DM). However, there is limited research on the clinical consequences of access barriers for these therapies.</div></div><div><h3>Objectives</h3><div>This study aimed to evaluate the impact of such barriers on hemoglobin A1c (HbA1c), weight, and body mass index (BMI) and examine how medication regimens are adjusted in response.</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was performed in a primary care setting. Adults with T2DM who were prescribed liraglutide, semaglutide, dulaglutide, exenatide, or tirzepatide between January 1, 2022, and July 31, 2024, were included. Patients were categorized based on exposure or no exposure to an access barrier. Access barriers were defined via a retrospective chart review.</div></div><div><h3>Results</h3><div>The primary outcome was the change in HbA1c. Patients with access barriers experienced a smaller reduction in HbA1c than those without (−0.42% vs. −0.75%, <em>P</em> = 0.2128). Secondary outcomes included changes in weight (−1.91 kg vs. −2.13 kg, <em>P</em> = 0.7022) and BMI (−0.7 vs. −0.75, <em>P</em> = 0.812). Common interventions that were performed by the clinic staff included providing medication samples and initiating alternative therapies such as insulin or sodium-glucose cotransporter 2 inhibitors during the delay period.</div></div><div><h3>Conclusion</h3><div>Although the study was underpowered to detect statistically significant differences, patients with documented access barriers had smaller reductions in HbA1c, weight, and BMI than those with uninterrupted therapy. These findings highlight the need for proactive strategies. Pharmacists can support patients by initiating alternative medications, providing medication samples if available, and developing clinic-wide protocols to manage shortages. Further research is needed to evaluate the long-term effects of interrupted GLP-1/GIP therapy owing to access barriers.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of discharges and graduations for a diverse patient population with socioeconomic barriers from a pharmacist-managed diabetes program","authors":"Katherine Houlihan,&nbsp;Jillian Cerullo,&nbsp;Megan Scalia,&nbsp;Darlene Tat","doi":"10.1016/j.japhpi.2026.100092","DOIUrl":"10.1016/j.japhpi.2026.100092","url":null,"abstract":"<div><h3>Background</h3><div>Collaborative practice agreements allow pharmacists to support multidisciplinary diabetes care and alleviate demands on primary care providers. More could be learned evaluating the percent hemoglobin A1c (A1C) reduction from enrollment to discharge and the percentage of patients who maintain A1C goal when next recorded in the electronic health record (EHR).</div></div><div><h3>Objectives</h3><div>The primary objective was to evaluate the percentage of patients who reached individualized A1C goals or “graduated” from the program. Secondary objectives included the percentage of patients who did not graduate, change in A1C, glucose-lowering medications at initial and final visits, maintenance of A1C goal after program completion, and the impact of language, ethnicity, race, and insurance type on graduation rates.</div></div><div><h3>Methods</h3><div>A retrospective chart review of 86 adults discharged from the pharmacist-managed diabetes program between January 1, 2023, and January 1, 2024, was conducted. Data collected included A1C at initial encounter, discharge, and follow-up; medications; demographics; and discharge reasons. Data were evaluated using descriptive statistics and logistic regression.</div></div><div><h3>Results</h3><div>Of 86 patients, 51 patients (64.6%) achieved individualized A1C goals within 500 days and graduated, whereas 17 (21.5%) were discharged for 3 or more no-shows. Of those who graduated, 66% maintained A1C goal when next recorded in the EHR. Mean A1C change was −2.68% for graduates and −0.47% in discharged patients. Pharmacist-managed care increased the use of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors. Graduation rates were lower among Spanish-speaking, Hispanic or Latino, and uninsured patients.</div></div><div><h3>Conclusion</h3><div>Pharmacist-managed diabetes care improved achievement and maintenance of A1C goals. Additional resources are needed to address socioeconomic and language barriers to program graduation.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of a pharmacist-run gout clinic in a VA community–based outpatient clinic","authors":"Francesca Reilly,&nbsp;Hunter Clark,&nbsp;Aleia Judd,&nbsp;Ashleigh Powers","doi":"10.1016/j.japhpi.2026.100098","DOIUrl":"10.1016/j.japhpi.2026.100098","url":null,"abstract":"<div><h3>Background</h3><div>Gout is a painful inflammatory disease common among men, older adults, and the obese. At the VA Tennessee Valley Healthcare System, 2792 patients prescribed urate-lowering therapy (ULT) had serum urate levels above target. In 2023, a pharmacist-run gout clinic was established to improve clinical outcomes and reduce gout burden among veterans. This biweekly clinic, run by a PGY-2 ambulatory care pharmacy resident, focused on assessing risks, managing treatments, and achieving serum uric acid (UA) levels.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the impact of a pharmacist-led gout clinic within a VA community–based outpatient clinic compared with standard primary care.</div></div><div><h3>Methods</h3><div>This retrospective matched cohort study compared outcomes from October 6, 2023, to May 17, 2024, between veterans managed in the pharmacist-led gout clinic (intervention group, n = 30) and those receiving standard primary care (control group, n = 30). Veterans managed by rheumatology or those lost to follow-up were excluded. The primary outcome was the percentage of veterans achieving the target serum UA level of less than 6 mg/dL. Secondary outcomes included emergency department (ED) visits or hospitalizations owing to gout flares, UA changes, therapy adjustments, and nonpharmacologic interventions.</div></div><div><h3>Results</h3><div>Sixty veterans were included, 30 in each group. Sixty percent of the intervention group achieved the primary outcome versus 10% in the control group (<em>P</em> &lt; 0.0001). The intervention group sustained UA control, greater reductions in UA, and more dose adjustments of ULT. All veterans seen by the pharmacist received nonpharmacologic interventions compared with 73.3% of those in the control group. Appropriate allopurinol dosing based on renal function was higher in the intervention group (100% vs. 86.7%). ED visits for acute gout flares were slightly higher in the intervention group (10% vs. 3.3%).</div></div><div><h3>Conclusion</h3><div>The pharmacist-run gout clinic significantly improved serum UA control and management interventions among veterans. These findings support expanding pharmacists’ roles in chronic disease management to enhance patient care.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100098"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists’ perceptions of artificial intelligence in specialty, outpatient, and inpatient pharmacy practice in New York state","authors":"Kevin Abraham,&nbsp;Carissa Escober Doran,&nbsp;Sara D’Anna,&nbsp;Daniela Farzadfar,&nbsp;Nina Chhabra,&nbsp;Norberto Collado,&nbsp;Christina Sam","doi":"10.1016/j.japhpi.2026.100114","DOIUrl":"10.1016/j.japhpi.2026.100114","url":null,"abstract":"<div><h3>Background</h3><div>Artificial intelligence (AI) tools, including large language models such as ChatGPT, Gemini, and Claude, are increasingly explored in health care. Although AI may enhance efficiency and accuracy, there are concerns regarding reliability, privacy, and liability. Limited data exist on pharmacists’ perceptions of AI in specialty and inpatient settings within large U.S. health systems.</div></div><div><h3>Objectives</h3><div>This study aimed to assess pharmacist familiarity, use, and perceptions of AI tools across VIVOHealth Pharmacies and Northwell Health inpatient hospital pharmacies and evaluate perceived benefits, concerns, and overall willingness to adopt.</div></div><div><h3>Methods</h3><div>A cross-sectional, electronic survey was distributed to pharmacists and pharmacy residents between August and September 2025. The 13-item survey collected demographics, familiarity, usage, benefits, concerns, trust, and willingness to adopt. Responses were summarized descriptively overall and stratified by gender and age.</div></div><div><h3>Results</h3><div>A total of 122 pharmacists and residents responded, representing specialty, outpatient, and inpatient settings across clinical, nonclinical, and administrator roles. Most respondents reported at least moderate familiarity with AI (61%), although use was concentrated in nonclinical tasks such as proofreading (50%) and literature summarization (44%), 3% used AI for clinical decision support, and 27% reported no use. Nearly half agreed that AI could improve accuracy, but concerns included information accuracy (82%), lack of human judgment (79%), and privacy risks (61%). Trust was limited, with most reporting somewhat or neutral trust. Although 89% supported AI education, 77% expressed willingness to adopt AI if institutionally validated. Gender and age differences were observed, with males and midcareer pharmacists reporting higher familiarity.</div></div><div><h3>Conclusion</h3><div>Pharmacists in specialty and inpatient settings expressed cautious optimism toward AI, recognizing potential benefits, while citing major concerns about accuracy, privacy, and judgment. These findings underscore the need for structured education, clear governance, and phased implementation strategies to ensure safe adoption of AI in pharmacy practice.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact of certified pharmacy technicians on behavioral health care management","authors":"Alyssa A. Longenecker,&nbsp;Jennifer Buxton,&nbsp;Sarah Logue,&nbsp;Ashley Sloop,&nbsp;Evelyn Ocana,&nbsp;Macary Weck Marciniak,&nbsp;Laura A. Rhodes","doi":"10.1016/j.japhpi.2026.100101","DOIUrl":"10.1016/j.japhpi.2026.100101","url":null,"abstract":"<div><h3>Background</h3><div>More than 50 million Americans experience a behavioral health illness. Adherence to prescribed medication is important for those with mental illness. Pharmacists are widely used health care providers, especially in rural areas with a limited number of mental health professionals. Owing to pharmacists’ increased duties, certified pharmacy technicians (CPhTs) can assume broader roles in patient care. Cape Fear Clinic serves rural counties wherein most patients experience a mental health illness. A CPhT intervention was implemented to assess the impact of ongoing care management after the initiation of a behavioral health medication.</div></div><div><h3>Objective</h3><div>The primary objective was to assess changes in Short Form Health Survey 12 (SF-12) scores after participation in a CPhT-led care management program. The secondary objectives were to assess behavioral health medication proportion of days covered (PDC) and suicidal/homicidal ideation at baseline and 12 weeks after the intervention.</div></div><div><h3>Methods</h3><div>Patients aged 18 years and older receiving a first-time prescription for a behavioral health medication or dose change were included. CPhTs contacted patients telephonically at enrollment and at 2, 4, 8, and 12 weeks after enrollment. Data collected at each touchpoint included SF-12 score, suicidal or homicidal ideation, and PDC. Results were analyzed using descriptive statistics.</div></div><div><h3>Results</h3><div>A total of 34 patients were enrolled; 9 patients (24%) completed the 12-week program. The average change in the SF-12 mental component score was +12.7 (baseline, 38.8; final, 51.5) and the SF-12 physical component score was −1.3 (baseline, 47.1; final, 45.8). Average PDC values were 71% (n = 1), 83% (n = 1), 87% (n = 1), and 100% (n = 6). Suicidal or homicidal ideation was positively reported in 7% of appointments (n = 6 of 86); 100% of positive findings (n = 6 of 6) were reported to the care team. There were 0 positive suicidal or homicidal ideation reports (0%) at program completion.</div></div><div><h3>Conclusion</h3><div>This CPhT-led care management service contributed to improved mental health, measured through SF-12 scores, and decreased positive suicidal ideation or homicidal ideation findings.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 3","pages":"Article 100101"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal of the American Pharmacists Association reviewers—2025","authors":"","doi":"10.1016/j.japhpi.2026.100102","DOIUrl":"10.1016/j.japhpi.2026.100102","url":null,"abstract":"","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 2","pages":"Article 100102"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147850720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Honoring our authors and peer reviewers","authors":"Pamela C. Heaton BSPharm, PhD, FAPhA","doi":"10.1016/j.japhpi.2026.100097","DOIUrl":"10.1016/j.japhpi.2026.100097","url":null,"abstract":"","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 2","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147850798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Implementation of pharmacist-prescribed contraceptive services: A case series of early adopters”","authors":"","doi":"10.1016/j.japhpi.2026.100095","DOIUrl":"10.1016/j.japhpi.2026.100095","url":null,"abstract":"","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"3 2","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147850719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}